citalopram has been researched along with Nausea in 23 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 9.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 9.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| "Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability." | 8.84 | Escitalopram therapy for major depression and anxiety disorders. ( Baldwin, DS; Guiton, C; Reines, EH; Weiller, E, 2007) |
| "The aim of the present study was to determine the relationship between the polymorphisms of -1438A/G and 102T/C in the 5-HT2A receptor (HTR2A) gene and nausea/vomiting as a side effect induced by sertraline (SERT) or citalopram (CIT) in patients with major depressive disorder." | 7.88 | The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. ( Baskak, B; Demirbugen Oz, M; Devrimci Ozguven, H; Kizil Ozel, T; Ozdemir, H; Suzen, HS; Uckun, Z; Yuce-Artun, N, 2018) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 7.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 5.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
"Escitalopram, a selective serotonin reuptake inhibitor (SSRI), was compared to placebo in a study of patients with major depressive disorder (DSM-IV) who had baseline Montgomery-Asberg Depression Rating Scale (MADRS) total scores >or=22 and | 5.10 | Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. ( Bang Hedegaard, K; Michael Lemming, O; Wade, A, 2002) | |
| "The aim of the study was to investigate the efficacy and safety of the selective serotonin reuptake inhibitor citalopram in treating poststroke depression, since available treatments are usually poorly tolerated." | 5.07 | Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. ( Andersen, G; Lauritzen, L; Vestergaard, K, 1994) |
| "Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability." | 4.84 | Escitalopram therapy for major depression and anxiety disorders. ( Baldwin, DS; Guiton, C; Reines, EH; Weiller, E, 2007) |
| "We identified an overexpression of miR185-5p during escitalopram treatment of major depressive disorder, which was negatively associated with intensity of nausea, and identified a potential mRNA target that may mediate this effect." | 3.96 | Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. ( Fiori, LM; Foster, JA; Frey, BN; Kennedy, SH; Lam, RW; MacQueen, GM; Milev, R; Müller, DJ; Turecki, G; Yrondi, A, 2020) |
| "The aim of the present study was to determine the relationship between the polymorphisms of -1438A/G and 102T/C in the 5-HT2A receptor (HTR2A) gene and nausea/vomiting as a side effect induced by sertraline (SERT) or citalopram (CIT) in patients with major depressive disorder." | 3.88 | The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. ( Baskak, B; Demirbugen Oz, M; Devrimci Ozguven, H; Kizil Ozel, T; Ozdemir, H; Suzen, HS; Uckun, Z; Yuce-Artun, N, 2018) |
| "To construct a cost-utility model comparing escitalopram with sertraline in the treatment of major depressive disorders." | 3.74 | Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. ( Armstrong, EP; Haim Erder, M; Skrepnek, GH, 2007) |
| "Escitalopram was used as a control for assay sensitivity." | 2.75 | A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. ( Dellva, MA; Dubé, S; Jones, M; Kielbasa, W; Padich, R; Rao, P; Saha, A, 2010) |
| "Escitalopram was found to exert a marked and a dose-dependent symptom-reducing effect, 20 mg/d being clearly superior to 10 mg/d." | 2.73 | Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. ( Ekman, A; Eriksson, E; Mattson, UB; Nissbrandt, H; Sinclair, S; Sörvik, K; Ysander, C, 2008) |
| "Escitalopram was well tolerated." | 2.72 | An open-label study of escitalopram in body dysmorphic disorder. ( Phillips, KA, 2006) |
| "Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders." | 2.72 | In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. ( Asenbaum, S; Attarbaschi, T; Dudczak, R; Geiss-Granadia, T; Holik, A; Kasper, S; Klein, N; Lanzenberger, R; Mossaheb, N; Pötzi, C; Sacher, J; Spindelegger, C; Tauscher, J, 2006) |
| "Citalopram was well tolerated, with only 15% of patients discontinuing for adverse events." | 2.69 | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. ( Feighner, JP; Overø, K, 1999) |
| " According to a previous in vitro study, this pharmacokinetic interaction occurs on the level of CYP2C19, but also of CYP2D6 and CYP3A4 which, in contrast to CYP1A2, contribute to the N-demethylation of citalopram and which are stereoselectively inhibited by fluvoxamine." | 2.68 | Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. ( Baumann, P; Bertschy, G; Bondolfi, G; Chautems, C; Rochat, B, 1996) |
| "Citalopram has been well tolerated in both short- and long-term use, and the profile seen in trials has been confirmed in the clinic." | 2.39 | The safety and tolerability of citalopram. ( Muldoon, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (39.13) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Yrondi, A | 1 |
| Fiori, LM | 1 |
| Frey, BN | 1 |
| Lam, RW | 1 |
| MacQueen, GM | 1 |
| Milev, R | 1 |
| Müller, DJ | 1 |
| Foster, JA | 1 |
| Kennedy, SH | 1 |
| Turecki, G | 1 |
| Demirbugen Oz, M | 1 |
| Uckun, Z | 1 |
| Yuce-Artun, N | 1 |
| Baskak, B | 1 |
| Ozdemir, H | 1 |
| Kizil Ozel, T | 1 |
| Devrimci Ozguven, H | 1 |
| Suzen, HS | 1 |
| Stamouli, SS | 1 |
| Yfantis, A | 1 |
| Lamboussis, E | 1 |
| Liakouras, A | 1 |
| Lagari, V | 1 |
| Tzanakaki, M | 1 |
| Giailoglou, D | 1 |
| Legault, M | 1 |
| Parashos, IA | 1 |
| Dubé, S | 1 |
| Dellva, MA | 1 |
| Jones, M | 1 |
| Kielbasa, W | 1 |
| Padich, R | 1 |
| Saha, A | 1 |
| Rao, P | 1 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Chiu, NY | 1 |
| Montgomery, SA | 1 |
| Huusom, AK | 1 |
| Bothmer, J | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Phillips, KA | 1 |
| Klein, N | 1 |
| Sacher, J | 1 |
| Geiss-Granadia, T | 1 |
| Attarbaschi, T | 1 |
| Mossaheb, N | 1 |
| Lanzenberger, R | 1 |
| Pötzi, C | 1 |
| Holik, A | 1 |
| Spindelegger, C | 1 |
| Asenbaum, S | 1 |
| Dudczak, R | 1 |
| Tauscher, J | 1 |
| Kasper, S | 1 |
| Armstrong, EP | 1 |
| Skrepnek, GH | 1 |
| Haim Erder, M | 1 |
| Hohage, H | 1 |
| Zeh, M | 1 |
| Baldwin, DS | 1 |
| Reines, EH | 1 |
| Guiton, C | 1 |
| Weiller, E | 1 |
| Eriksson, E | 1 |
| Ekman, A | 1 |
| Sinclair, S | 1 |
| Sörvik, K | 1 |
| Ysander, C | 1 |
| Mattson, UB | 1 |
| Nissbrandt, H | 1 |
| Andersen, G | 1 |
| Vestergaard, K | 1 |
| Lauritzen, L | 1 |
| Muldoon, C | 1 |
| Patris, M | 1 |
| Bouchard, JM | 1 |
| Bougerol, T | 1 |
| Charbonnier, JF | 1 |
| Chevalier, JF | 1 |
| Clerc, G | 1 |
| Cyran, C | 1 |
| Van Amerongen, P | 1 |
| Lemming, O | 1 |
| Høpfner Petersen, HE | 1 |
| Haffmans, PM | 1 |
| Timmerman, L | 1 |
| Hoogduin, CA | 1 |
| Bondolfi, G | 1 |
| Chautems, C | 1 |
| Rochat, B | 1 |
| Bertschy, G | 1 |
| Baumann, P | 1 |
| Pedersen, L | 1 |
| Klysner, R | 1 |
| Ekselius, L | 1 |
| von Knorring, L | 1 |
| Eberhard, G | 1 |
| Feighner, JP | 1 |
| Overø, K | 1 |
| Wade, A | 1 |
| Michael Lemming, O | 1 |
| Bang Hedegaard, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)[NCT05017311] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for citalopram and Nausea
| Article | Year |
|---|---|
Escitalopram therapy for major depression and anxiety disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Depressive Disorder, Majo | 2007 |
The safety and tolerability of citalopram.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorde | 1996 |
13 trials available for citalopram and Nausea
| Article | Year |
|---|---|
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Citalopram; Constipati | 2010 |
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Constipation; Cyclohexanols; Delayed-Ac | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
An open-label study of escitalopram in body dysmorphic disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Midd | 2006 |
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Topics: Administration, Oral; Adult; Akathisia, Drug-Induced; Area Under Curve; Cerebellum; Cinanserin; Cita | 2006 |
Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.
Topics: Adult; Capsules; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Re | 2008 |
Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Citalopram; Cohort Studies; Depression; D | 1994 |
Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; | 1996 |
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Double-Blind Method; Female | 1996 |
Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Drug Resistance; Drug Synergism; Drug | 1996 |
A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Diarrhea; Doub | 1997 |
Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Topics: Administration, Oral; Adult; Ambulatory Care; Citalopram; Depressive Disorder; Drug Administration S | 1999 |
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Citalopram; Depressive Disorder; Double-Blind Method; | 2002 |
8 other studies available for citalopram and Nausea
| Article | Year |
|---|---|
Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report.
Topics: Adolescent; Adult; Citalopram; Cohort Studies; Depressive Disorder, Major; Female; Gene Expression; | 2020 |
The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Fe | 2018 |
Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anxiety; Citalopram; Depressive Disorder, Major; Female; G | 2009 |
Escitalopram for psychogenic nausea and vomiting: a report of two cases.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; | 2011 |
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Depres | 2007 |
[Nausea and confusion in a diabetic patient. Hyponatremia as an incidental finding].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Confusion; Diabetes Mellitus; Diagnosis, Diffe | 2006 |
Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder; Female; | 1997 |
Citalopram for depression.
Topics: Citalopram; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Double-Blind Met | 1998 |